The AI ECG Cardiology Market After Queen of Hearts: Who the De Novo Clearance Actually Benefits
Dr. Dereck Mush, MD, MBA
CorFlow
Diagnoses coronary microvascular dysfunction during standard interventional cardiology procedures.
What they do
Develops a proprietary medical system that measures coronary microvascular status in the catheterization lab. The device allows interventional cardiologists to diagnose and assess microvascular obstruction immediately following a heart attack, guiding post procedure treatment.
The record
- Vertical
- Cardiovascular
- Sub-segment
- Microvascular diagnostics
- Product type
- Diagnostics
- Stage
- Series B
- Headquarters
- Baar, Switzerland
- Region
- Europe
- Founded
- 2016
- Total funding
- $44M raised
Notable investors: Broadview Ventures, 415 Capital, Kromap, Sisu Medical Ventures.
Also in Cardiovascular
Related on The Signal
Dr. Dereck Mush, MD, MBA
Bridging the Last Mile of Acute Cardiology: Synthesized 3D Vectorcardiography at Home
Dr. Dereck Mush, MD, MBA
Point-of-Care Ultrasound Is the Quiet Revolution in Diagnostics
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
The 8 Best AI Diagnostic Tools of 2026
AI diagnostics stopped being experimental. These eight tools are FDA-cleared, deployed at scale, and quietly changing how disease gets found.
Dr. Dereck Mush, MD, MBA